Koji Miyahara

Koji Miyahara

Auto-generated profile, based on publicly available information

Koji Miyahara

Department of Internal Medicine Hiroshima City Hiroshima Citizens Hospital Hiroshima Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
KMKoji Miyahara
Koji Miyahara
The kinase inhibitor sorafenib is the only systemic therapy proven to have a positive effect on survival of patients with advanced hepatocellular carcinoma (HCC). After development of sorafenib and its introduction as a therapeutic agent used in the clinic, several critical questions have been raised. Clinical parameters and biomarkers predicting sorafenib efficacy are the most important issues that need to be elucidated. Although it is difficult to know the responders in advance using conventional characteristics of patients, there are specific serum cytokines and/or gene amplification in tumor tissues that have been reported to predict efficacy of sorafenib. Risk and benefits of continuation of sorafenib beyond radiological progression is another issue to consider because no other standard therapy for advanced HCC as yet exists. In addition, effectiveness of the expanded application of sorafenib is still controversial, although a few studies have shed some light on combinational treatment with sorafenib for intermediate-stage HCC. Recently, over 50 relevant drugs have been developed and are currently under investigation. The efficacy of some of these drugs has been extensively examined, but none have demonstrated any superiority over sorafenib, so far. However, there are several drugs that have shown efficacy for treatment after sorafenib failure, and these are proceeding to further studies. To address these issues and questions, we have done extensive literature review and summarize the most current status of therapeutic application of sorafenib.

28 August 2014 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
YYYasushi Yamasaki
Yasushi Yamasaki
Kazuhiro NousoKazuhiro Nouso
Kazuhiro Nouso
KMKoji Miyahara
Koji Miyahara
NWNozomu Wada
Nozomu Wada
CDChihiro Dohi
Chihiro Dohi
KYKazuhide Yamamoto
Kazuhide Yamamoto
Background and Aims: Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non‐alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non‐alcoholic steatohepatitis (NASH) from simple steatosis (SS).Methods: We collected sera from 42 histologically proven NASH and 15 SS patients prior to treatment. Serum glycan profiles were measured by comprehensive, quantitative, high‐throughput glycome analysis, and diagnostic values of serum glycans for NASH prediction were examined.Results: Among the 41 serum glycans examined, the expression levels of 8 glycans in NASH were significantly higher than those of SS. Out of these eight glycans, three glycans (m/z 1955, 2032, and 2584) showed high areas under the receiver operating characteristic curve (0.833, 0.863, and 0.866, respectively) for distinguishing NASH from SS. In multivariate analyses with clinical parameters and serum glycans, these three glycans were significant predictive factors for distinguishing NASH from SS. The odds ratio of m/z 1955, 2032, and 2584 were 48.5, 6.46, and 11.8, respectively. These glycans also correlated significantly with lobular inflammation, ballooning, and fibrosis, but not with steatosis.Conclusion: We clearly demonstrated whole‐serum glycan profiles in NASH patients, and the feasibility of serum glycans (m/z 1955, 2032, and 2584) as new noninvasive biomarkers for distinguishing NASH from SS.

31 May 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
KMKoji Miyahara
Koji Miyahara
Kazuhiro NousoKazuhiro Nouso
Kazuhiro Nouso
YMYasuhiro Miyake
Yasuhiro Miyake
SNShinichiro Nakamura
Shinichiro Nakamura
SOShuntaro Obi
Shuntaro Obi
KYKazuhide Yamamoto
Kazuhide Yamamoto

27 June 2025 in The Journal of Dermatology
Verified
Journal Article
Closed access
KMKoji Miyahara
Koji Miyahara
MMMarie Matsumoto
Marie Matsumoto
MKMasaki Kunihiro
Masaki Kunihiro
YTYoichiro Toi
Yoichiro Toi
MHMichihiro Hide
Michihiro Hide